Tobramycin-treated Pseudomonas aeruginosa PA14 enhances Streptococcus constellatus 7155 biofilm formation in a cystic fibrosis model system

Journal of Bacteriology

Volumn 198, Issue 2, 2016, Pages 237-247

  Price, Katherine E ^a   Naimie, Amanda A ^a   Griffin, Edward F ^a   Bay, Charles ^b   O'Toole, George A ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b DARTMOUTH INSTITUTE FOR HEALTH POLICY AND CLINICAL PRACTICE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RHAMNOLIPID; TOBRAMYCIN; ANTIINFECTIVE AGENT; GLYCOLIPID;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL GENE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIAL VIABILITY; BACTERIUM COLONY; BIOFILM; CELL DAMAGE; CELL GROWTH; CELL SURFACE; COLONY FORMING UNIT; CONTROLLED STUDY; CYSTIC FIBROSIS; CYTOTOXICITY; DISEASE EXACERBATION; FUSOBACTERIUM NUCLEATUM; GEMELLA; GENE EXPRESSION; GENE MUTATION; GENE REPRESSION; GENETIC SCREENING; GROWTH INHIBITION; GROWTH RATE; GROWTH STIMULATION; HEAT; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LIMIT OF DETECTION; LIPOGENESIS; LUNG ALVEOLUS CELL; LUNG FUNCTION; MICROBIAL COMMUNITY; MIXED INFECTION; NONHUMAN; NUTRIENT AVAILABILITY; ORGANISMAL INTERACTION; PATHOGENESIS; PHENOTYPE; PREVOTELLA INTERMEDIA; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; QUORUM SENSING; STAPHYLOCOCCUS AUREUS; STENOTROPHOMONAS MALTOPHILIA; STREPTOCOCCUS CONSTELLATUS; COCULTURE; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; METABOLISM; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; PHYSIOLOGY;

ANTI-BACTERIAL AGENTS; BACTERIOLOGICAL TECHNIQUES; BIOFILMS; COCULTURE TECHNIQUES; CYSTIC FIBROSIS; GLYCOLIPIDS; HUMANS; PSEUDOMONAS AERUGINOSA; STREPTOCOCCUS CONSTELLATUS; TOBRAMYCIN;

EID: 84953897465     PISSN: 00219193     EISSN: 10985530     Source Type: Journal    
DOI: 10.1128/JB.00705-15     Document Type: Article

References (49)

1. Costerton JW. 2001. Cystic fibrosis pathogenesis and the role of biofilms in persistent infection. Trends Microbiol 9:50-52. http://dx.doi.org/10.1016/S0966-842X(00)01918-1.
2. Heijerman H. 2005. Infection and inflammation in cystic fibrosis: a short review. J Cyst Fibros 4(Suppl 2):S3-S5.
3. Lyczak JB, Cannon CL, Pier GB. 2002. Lung infections associated with cystic fibrosis. Clin Microbiol Rev 15:194-222. http://dx.doi.org/10.1128/CMR.15.2.194-222.2002.
4. Zhao J, Schloss PD, Kalikin LM, Carmody LA, Foster BK, Petrosino JF, Cavalcoli JD, VanDevanter DR, Murray S, Li JZ, Young VB, LiPuma JJ. 2012. Decade-long bacterial community dynamics in cystic fibrosis airways. Proc Natl Acad Sci U S A 109:5809-5814. http://dx.doi.org/10.1073/pnas.1120577109.
5. Fodor AA, Klem ER, Gilpin DF, Elborn JS, Boucher RC, Tunney MM, Wolfgang MC. 2012. The adult cystic fibrosis airway microbiota is stable over time and infection type, and highly resilient to antibiotic treatment of exacerbations. PLoS One 7:e45001. http://dx.doi.org/10.1371/journal.pone.0045001.
6. Filkins LM, Hampton TH, Gifford AH, Gross MJ, Hogan DA, Sogin ML, Morrison HG, Paster BJ, O'Toole GA. 2012. Prevalence of streptococci and increased polymicrobial diversity associated with cystic fibrosis patient stability. J Bacteriol 194:4709-4717. http://dx.doi.org/10.1128/JB.00566-12.
7. Lim YW, Schmieder R, Haynes M, Willner D, Furlan M, Youle M, Abbott K, Edwards R, Evangelista J, Conrad D, Rohwer F. 2013. Metagenomics and metatranscriptomics: windows on CF-associated viral and microbial communities. J Cyst Fibros 12:154-164. http://dx.doi.org/10.1016/j.jcf.2012.07.009.
8. Stressmann FA, Rogers GB, van der Gast CJ, Marsh P, Vermeer LS, Carroll MP, Hoffman L, Daniels TW, Patel N, Forbes B, Bruce KD. 2012. Long-term cultivation-independent microbial diversity analysis demonstrates that bacterial communities infecting the adult cystic fibrosis lung show stability and resilience. Thorax 67:867-873. http://dx.doi.org/10.1136/thoraxjnl-2011-200932.
9. Price KE, Hampton TH, Gifford AH, Dolben EL, Hogan DA, Morrison HG, Sogin ML, O'Toole GA. 2013. Unique microbial communities persist in individual cystic fibrosis patients throughout a clinical exacerbation. Microbiome 1:27. http://dx.doi.org/10.1186/2049-2618-1-27.
10. Zemanick ET, Harris JK, Wagner BD, Robertson CE, Sagel SD, Stevens MJ, Accurso FJ, Laguna TA. 2013. Inflammation and airway microbiota during cystic fibrosis pulmonary exacerbations. PLoS One 8:e62917. http://dx.doi.org/10.1371/journal.pone.0062917.
11. Sibley CD, Grinwis ME, Field TR, Parkins MD, Norgaard JC, Gregson DB, Rabin HR, Surette MG. 2010. McKay agar enables routine quantification of the 'Streptococcus milleri' group in cystic fibrosis patients. J Med Microbiol 59:534-540. http://dx.doi.org/10.1099/jmm.0.016592-0.
12. Sibley CD, Parkins MD, Rabin HR, Duan K, Norgaard JC, Surette MG. 2008. A polymicrobial perspective of pulmonary infections exposes an enigmatic pathogen in cystic fibrosis patients. Proc Natl Acad Sci U S A 105:15070-15075. http://dx.doi.org/10.1073/pnas.0804326105.
13. Field TR, Sibley CD, Parkins MD, Rabin HR, Surette MG. 2010. The genus Prevotella in cystic fibrosis airways. Anaerobe 16:337-344. http://dx.doi.org/10.1016/j.anaerobe.2010.04.002.
14. Duan K, Dammel C, Stein J, Rabin H, Surette MG. 2003. Modulation of Pseudomonas aeruginosa gene expression by host microflora through interspecies communication. Mol Microbiol 50:1477-1491. http://dx.doi.org/10.1046/j.1365-2958.2003.03803.x.
15. Riedele C, Reichl U. 2011. Interspecies effects in a ceftazidime-treated mixed culture of Pseudomonas aeruginosa, Burkholderia cepacia and Staphylococcus aureus: analysis at the single-species level. J Antimicrob Chemother 66:138-145. http://dx.doi.org/10.1093/jac/dkq394.
16. Hibbing ME, Fuqua C, Parsek MR, Peterson SB. 2010. Bacterial competition: surviving and thriving in the microbial jungle. Nat Rev Microbiol 8:15-25. http://dx.doi.org/10.1038/nrmicro2259.
17. Stacy A, Everett J, Jorth P, Trivedi U, Rumbaugh KP, Whiteley M. 2014. Bacterial fight-and-flight responses enhance virulence in a polymicrobial infection. Proc Natl Acad Sci U S A 111:7819-7824. http://dx.doi.org/10.1073/pnas.1400586111.
18. Tunney MM, Klem ER, Fodor AA, Gilpin DF, Moriarty TF, McGrath SJ, Muhlebach MS, Boucher RC, Cardwell C, Doering G, Elborn JS, Wolfgang MC. 2011. Use of culture and molecular analysis to determine the effect of antibiotic treatment on microbial community diversity and abundance during exacerbation in patients with cystic fibrosis. Thorax 66:579-584. http://dx.doi.org/10.1136/thx.2010.137281.
19. Parkins MD, Sibley CD, Surette MG, Rabin HR. 2008. The Streptococcus milleri group-an unrecognized cause of disease in cystic fibrosis: a case series and literature review. Pediatr Pulmonol 43:490-497. http://dx.doi.org/10.1002/ppul.20809.
20. Anderson GG, Moreau-Marquis S, Stanton BA, O'Toole GA. 2008. In vitro analysis of tobramycin-treated Pseudomonas aeruginosa biofilms on cystic fibrosis-derived airway epithelial cells. Infect Immun 76:1423-1433. http://dx.doi.org/10.1128/IAI.01373-07.
21. Filkins LM, Graber JA, Olson DG, Dolben EL, Lynd LR, Bhuju S, O'Toole GA. 2015. Coculture of Staphylococcus aureus with Pseudomonas aeruginosa drives S. aureus towards fermentative metabolism and reduced viability in a cystic fibrosis model. J Bacteriol 197:2252-2264. http://dx.doi.org/10.1128/JB.00059-15.
22. Moreau-Marquis S, Bomberger JM, Anderson GG, Swiatecka-Urban A, Ye S, O'Toole GA, Stanton BA. 2008. The DeltaF508-CFTR mutation results in increased biofilm formation by Pseudomonas aeruginosa by increasing iron availability. Am J Physiol Lung Cell Mol Physiol 295:L25-L37. http://dx.doi.org/10.1152/ajplung.00391.2007.
23. - secretion in human subjects by adenosine. Am J Respir Cell Mol Biol 31:140-146. http://dx.doi.org/10.1165/rcmb.2004-0012OC.
24. Bruscia E, Sangiuolo F, Sinibaldi P, Goncz KK, Novelli G, Gruenert DC. 2002. Isolation of CF cell lines corrected at DeltaF508-CFTR locus by SFHR-mediated targeting. Gene Ther 9:683-685. http://dx.doi.org/10.1038/sj.gt.3301741.
25. Cozens AL, Yezzi MJ, Kunzelmann K, Ohrui T, Chin L, Eng K, Finkbeiner WE, Widdicombe JH, Gruenert DC. 1994. CFTR expression and chloride secretion in polarized immortal human bronchial epithelial cells. Am J Respir Cell Mol Biol 10:38-47. http://dx.doi.org/10.1165/ajrcmb.10.1.7507342.
26. Bloemberg GV, O'Toole GA, Lugtenberg BJ, Kolter R. 1997. Green fluorescent protein as a marker for Pseudomonas spp. Appl Environ Microbiol 63:4543-4551.
27. Deziel E, Comeau Y, Villemur R. 2001. Initiation of biofilm formation by Pseudomonas aeruginosa 57RP correlates with emergence of hyperpiliated and highly adherent phenotypic variants deficient in swimming, swarming, and twitching motilities. J Bacteriol 183:1195-1204. http://dx.doi.org/10.1128/JB.183.4.1195-1204.2001.
28. Caiazza NC, Shanks RM, O'Toole GA. 2005. Rhamnolipids modulate swarming motility patterns of Pseudomonas aeruginosa. J Bacteriol 187:7351-7361. http://dx.doi.org/10.1128/JB.187.21.7351-7361.2005.
29. Mason DJ, Shanmuganathan S, Mortimer FC, Gant VA. 1998. A fluorescent Gram stain for flow cytometry and epifluorescence microscopy. Appl Environ Microbiol 64:2681-2685.
30. Hoffman LR, D'Argenio DA, MacCoss MJ, Zhang Z, Jones RA, Miller SI. 2005. Aminoglycoside antibiotics induce bacterial biofilm formation. Nature 436:1171-1175. http://dx.doi.org/10.1038/nature03912.
31. Whiteley M, Bangera MG, Bumgarner RE, Parsek MR, Teitzel GM, Lory S, Greenberg EP. 2001. Gene expression in Pseudomonas aeruginosa biofilms. Nature 413:860-864. http://dx.doi.org/10.1038/35101627.
32. Marr AK, Gooderham WJ, Hancock RE. 2006. Antibacterial peptides for therapeutic use: obstacles and realistic outlook. Curr Opin Pharmacol 6:468-472. http://dx.doi.org/10.1016/j.coph.2006.04.006.
33. Linares JF, Gustafsson I, Baquero F, Martinez JL. 2006. Antibiotics as intermicrobial signaling agents instead of weapons. Proc Natl Acad Sci U S A 103:19484-19489. http://dx.doi.org/10.1073/pnas.0608949103.
34. Kindrachuk KN, Fernández L, Bains M, Hancock RE. 2011. Involvement of an ATP-dependent protease, PA0779/AsrA, in inducing heat shock in response to tobramycin in Pseudomonas aeruginosa. Antimicrob Agents Chemother 55:1874-1882. http://dx.doi.org/10.1128/AAC.00935-10.
35. Bjarnsholt T, Jensen PO, Burmolle M, Hentzer M, Haagensen JA, Hougen HP, Calum H, Madsen KG, Moser C, Molin S, Hoiby N, Givskov M. 2005. Pseudomonas aeruginosa tolerance to tobramycin, hydrogen peroxide and polymorphonuclear leukocytes is quorum-sensing dependent. Microbiology 151:373-383. http://dx.doi.org/10.1099/mic.0.27463-0.
36. Babić F, Venturi V, Maravić-Vlahoviček G. 2010. Tobramycin at subinhibitory concentration inhibits the RhlI/R quorum sensing system in a Pseudomonas aeruginosa environmental isolate. BMC Infect Dis 10:148. http://dx.doi.org/10.1186/1471-2334-10-148.
37. Ochsner UA, Fiechter A, Reiser J. 1994. Isolation, characterization, and expression in Escherichia coli of the Pseudomonas aeruginosa rhlAB genes encoding a rhamnosyltransferase involved in rhamnolipid biosurfactant synthesis. J Biol Chem 269:19787-19795.
38. Ochsner UA, Koch AK, Fiechter A, Reiser J. 1994. Isolation and characterization of a regulatory gene affecting rhamnolipid biosurfactant synthesis in Pseudomonas aeruginosa. J Bacteriol 176:2044-2054.
39. Rahim R, Ochsner UA, Olvera C, Graninger M, Messner P, Lam JS, Soberón-Chávez G. 2001. Cloning and functional characterization of the Pseudomonas aeruginosa rhlC gene that encodes rhamnosyltransferase 2, an enzyme responsible for di-rhamnolipid biosynthesis. Mol Microbiol 40:708-718. http://dx.doi.org/10.1046/j.1365-2958.2001.02420.x.
40. Ochsner UA, Reiser J. 1995. Autoinducer-mediated regulation of rhamnolipid biosurfactant synthesis in Pseudomonas aeruginosa. Proc Natl Acad Sci U S A 92:6424-6428. http://dx.doi.org/10.1073/pnas.92.14.6424.
41. Boles BR, Thoendel M, Singh PK. 2005. Rhamnolipids mediate detachment of Pseudomonas aeruginosa from biofilms. Mol Microbiol 57:1210-1223. http://dx.doi.org/10.1111/j.1365-2958.2005.04743.x.
42. Haba E, Pinazo A, Jauregui O, Espuny MJ, Infante MR, Manresa A. 2003. Physicochemical characterization and antimicrobial properties of rhamnolipids produced by Pseudomonas aeruginosa 47T2 NCBIM 40044. Biotechnol Bioeng 81:316-322. http://dx.doi.org/10.1002/bit.10474.
43. Davey ME, Caiazza NC, O'Toole GA. 2003. Rhamnolipid surfactant production affects biofilm architecture in Pseudomonas aeruginosa PAO1. J Bacteriol 185:1027-1036. http://dx.doi.org/10.1128/JB.185.3.1027-1036.2003.
44. Kownatzki R, Tümmler B, Döring G. 1987. Rhamnolipid of Pseudomonas aeruginosa in sputum of cystic fibrosis patients. Lancet i:1026-1027.
45. Smith EE, Buckley DG, Wu Z, Saenphimmachak C, Hoffman LR, D'Argenio DA, Miller SI, Ramsey BW, Speert DP, Moskowitz SM, Burns JL, Kaul R, Olson MV. 2006. Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc Natl Acad Sci U S A 103:8487-8492. http://dx.doi.org/10.1073/pnas.0602138103.
46. Mashburn LM, Jett AM, Akins DR, Whiteley M. 2005. Staphylococcus aureus serves as an iron source for Pseudomonas aeruginosa during in vivo coculture. J Bacteriol 187:554-566. http://dx.doi.org/10.1128/JB.187.2.554-566.2005.
47. Korgaonkar A, Trivedi U, Rumbaugh KP, Whiteley M. 2013. Community surveillance enhances Pseudomonas aeruginosa virulence during polymicrobial infection. Proc Natl Acad Sci U S A 110:1059-1064. http://dx.doi.org/10.1073/pnas.1214550110.
48. Whiteson KL, Meinardi S, Lim YW, Schmieder R, Maughan H, Quinn R, Blake DR, Conrad D, Rohwer F. 2014. Breath gas metabolites and bacterial metagenomes from cystic fibrosis airways indicate active pH neutral 2,3-butanedione fermentation. ISME J 8:1247-1258. http://dx.doi.org/10.1038/ismej.2013.229.
49. Wang Y, Newman DK. 2008. Redox reactions of phenazine antibiotics with ferric (hydr)oxides and molecular oxygen. Environ Sci Technol 42:2380-2386. http://dx.doi.org/10.1021/es702290a.